Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3643307 | 1.00 | CYP4F2 (0.31) | CYP4F2CYP4A11 | |
| SCHEMBL375134 | 1.00 | CYP4F2 (0.31) | CYP4F2CYP4A11 | |
| SCHEMBL375254 | 0.91 | CYP4F2 (0.33) | CYP4F2CYP4A11 | |
| SCHEMBL20348813 | 0.86 | CYP4F2 (0.33) | CYP4F2CYP4A11 | |
| SCHEMBL3292857 | 0.83 | — | — | |
| SCHEMBL15928651 | 0.79 | SMN1; SMN2 (0.34) | — | |
| SCHEMBL1536298 | 0.79 | GRM2 (0.35) | — | |
| SCHEMBL7392445 | 0.79 | MAPK1 (0.36) | — | |
| SCHEMBL7392443 | 0.79 | MAPK1 (0.36) | — | |
| SCHEMBL7392441 | 0.79 | MAPK1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932277-B2 | Peptide inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-20090297476-A1 | NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090297476-A1 | NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | VIP, HDGF, EIF2AK2 | CYP4F2 3811/4885CYP4A11 3384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.